Dexcom Inc is a leading company specializing in continuous glucose monitoring systems for individuals with diabetes. Their innovative technology enables users to track glucose levels in real time through a small sensor placed under the skin, eliminating the need for traditional fingerstick testing. The company's products empower patients and healthcare providers to make informed decisions regarding diabetes management, enhancing the quality of life for those living with the condition. By integrating advanced software and mobile applications, Dexcom's systems deliver essential insights and alerts, contributing to better health outcomes for users. Read More
NEW YORK, NY - November 6, 2025 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM) on behalf of investors that purchased or otherwise acquired DexCom securities between July 26, 2024 and September 17, 2025 (the “Class Period”).
NEW YORK - November 6, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in DexCom, Inc. (NASDAQ: DXCM) of a class action securities lawsuit.
DexCom's third quarter was met with a negative market reaction despite outpacing Wall Street’s revenue and adjusted EPS expectations. Management attributed quarterly growth to increased continuous glucose monitoring (CGM) adoption among people with type 2 diabetes, particularly following expanded insurance coverage and deeper reach into primary care. Interim CEO Jacob Leach emphasized the impact of new product features and improved access, but also acknowledged lingering manufacturing and sensor deployment issues that affected sensor supply and user experience. As Leach stated, "We have addressed deployment challenges and continue to improve sensor quality, but will not be satisfied until every customer expectation is met."
NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds investors who purchased DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ:DXCM) securities to contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests in the securities fraud class action lawsuit at no cost.
The Nasdaq 100 (^NDX) is where investors find some of the most innovative and disruptive companies shaping the future.
A select few continue to execute at a high level, growing their market dominance and delivering strong returns.
RADNOR, PA - November 5, 2025 ( NEWMEDIAWIRE ) - The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed against DexCom, Inc. (“DexCom”) ( NASDAQ: DXCM ) on behalf of those who purchased or otherwise acquired DexCom securities between July 26, 2024, and September 17, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is December 26, 2025.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In DexCom (DXCM) To Contact Him Directly To Discuss Their Options
NEW YORK - November 5, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in DexCom, Inc. (NASDAQ: DXCM) of a class action securities lawsuit.
LOS ANGELES, Nov. 04, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against DexCom, Inc. (“DexCom” or “the Company”) (NASDAQ: DXCM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
RADNOR, PA - November 4, 2025 ( NEWMEDIAWIRE ) - The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed against DexCom, Inc. (“DexCom”) ( NASDAQ: DXCM ) on behalf of those who purchased or otherwise acquired DexCom securities between July 26, 2024, and September 17, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is December 26, 2025.
Shares of medical device company DexCom (NASDAQ:DXCM)
jumped 3.7% in the afternoon session after it rebounded from a steep sell-off that was triggered by its long-term revenue growth outlook. The stock had previously plunged more than 14% after the company's interim CEO stated during its third-quarter earnings call that revenue growth for 2026 could fall short of analyst expectations. This cautious forecast overshadowed an otherwise strong report, in which the company beat third-quarter earnings and revenue estimates. DexCom also raised its full-year 2025 revenue outlook. The sharp drop in previous sessions suggested investors focused more on the future growth warning than the positive current results, and the subsequent modest gain indicated some bargain hunting.
Curious about the top performers within the S&P500 index in the middle of the day on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
RADNOR, PA - November 3, 2025 ( NEWMEDIAWIRE ) - The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed against DexCom, Inc. (“DexCom”) ( NASDAQ: DXCM ) on behalf of those who purchased or otherwise acquired DexCom securities between July 26, 2024, and September 17, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is December 26, 2025.
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Friday as we examine the latest happenings in today's session.
